Is GlobalFoundries On The Verge Of A Breakout?
GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…
Sell
36
APLS Quote, Financials, Valuation and Earnings
Last price:
$17.43
Seasonality move
:
5.74%
Day range:
$17.23 - $18.39
52-week range:
$16.10 - $43.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.80x
P/B ratio:
13.33x
Volume:
1.8M
Avg. volume:
2.9M
1-year change:
-59.07%
Market cap:
$2.2B
Revenue:
$781.4M
EPS (TTM):
-$1.79
Analysts' Opinion
-
Consensus RatingApellis Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $37.48, Apellis Pharmaceuticals has an estimated upside of 115.13% from its current price of $17.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $17.42.
Fair Value
-
According to the consensus of 19 analysts, Apellis Pharmaceuticals has 115.13% upside to fair value with a price target of $37.48 per share.
APLS vs. S&P 500
-
Over the past 5 trading days, Apellis Pharmaceuticals has overperformed the S&P 500 by 6.34% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Apellis Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Apellis Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Apellis Pharmaceuticals reported revenues of $166.8M.
Earnings Growth
-
Apellis Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Apellis Pharmaceuticals reported earnings per share of -$0.74.
Enterprise value:
2.3B
EV / Invested capital:
3.70x
Price / LTM sales:
2.80x
EV / EBIT:
--
EV / Revenue:
2.94x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-271.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$644M
Return On Assets:
-25.83%
Net Income Margin (TTM):
-28.83%
Return On Equity:
-96.34%
Return On Invested Capital:
-36.43%
Operating Margin:
-49.96%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $105.9M | $524.1M | $775.8M | $172.3M | $166.8M | |
| Gross Profit | $93.7M | $453.2M | $644M | $152.1M | $132.4M | |
| Operating Income | -$640.7M | -$404.1M | -$186.2M | -$62.1M | -$83.3M | |
| EBITDA | -$658.1M | -$384.4M | -$176.1M | -$58.8M | -$80.4M | |
| Diluted EPS | -$6.27 | -$3.46 | -$1.79 | -$0.54 | -$0.74 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $773.6M | $1.1B | $954.3M | $811.4M | $727.7M | |
| Total Assets | $810.1M | $1.1B | $978.9M | $831.9M | $807.3M | |
| Current Liabilities | $83.7M | $124.8M | $138.6M | $215.3M | $178.4M | |
| Total Liabilities | $758.5M | $683.6M | $566.7M | $565.3M | $643.1M | |
| Total Equity | $51.7M | $462.2M | $412.1M | $266.7M | $164.2M | |
| Total Debt | $386.2M | $189.2M | $92.8M | $93.1M | $453.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$579.8M | -$550.1M | -$8.3M | -$133M | -$53.4M | |
| Cash From Investing | $331.6M | -$708K | -$118K | -$293K | -$8K | |
| Cash From Financing | $380.1M | $111.6M | $41.3M | $108.2M | $274K | |
| Free Cash Flow | -$581.5M | -$550.9M | -$8.4M | -$133.3M | -$53.4M | |
APLS
Sector
Market Cap
$2.2B
$34.2M
Price % of 52-Week High
39.6%
43.73%
Dividend Yield
0%
0%
Shareholder Yield
-1.81%
-0.66%
1-Year Price Total Return
-59.07%
-41.71%
Beta (5-Year)
0.725
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$17.36
200-day SMA
Sell
Level
$28.74
Bollinger Bands (100)
Sell
Level
19.49 - 30.01
Chaikin Money Flow
Sell
Level
-29.7M
20-day SMA
Sell
Level
$18.10
Relative Strength Index (RSI14)
Sell
Level
42.25
ADX Line
Sell
Level
30.51
Williams %R
Neutral
Level
-71.6129
50-day SMA
Sell
Level
$20.26
MACD (12, 26)
Sell
Level
-0.76
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Sell
Level
-72.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0526)
Sell
CA Score
(Annual)
Level (-2.0757)
Sell
Beneish M-Score
(Annual)
Level (18.131)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.1882)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Stock Forecast FAQ
In the current month, APLS has received 11 Buy ratings 8 Hold ratings, and 0 Sell ratings. The APLS average analyst price target in the past 3 months is $37.48.
-
Where Will Apellis Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Apellis Pharmaceuticals share price will rise to $37.48 per share over the next 12 months.
-
What Do Analysts Say About Apellis Pharmaceuticals?
Analysts are divided on their view about Apellis Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Apellis Pharmaceuticals is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is Apellis Pharmaceuticals's Price Target?
The price target for Apellis Pharmaceuticals over the next 1-year time period is forecast to be $37.48 according to 19 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is APLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Apellis Pharmaceuticals is a Buy. 11 of 19 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of APLS?
You can purchase shares of Apellis Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Apellis Pharmaceuticals shares.
-
What Is The Apellis Pharmaceuticals Share Price Today?
Apellis Pharmaceuticals was last trading at $17.43 per share. This represents the most recent stock quote for Apellis Pharmaceuticals. Yesterday, Apellis Pharmaceuticals closed at $17.42 per share.
-
How To Buy Apellis Pharmaceuticals Stock Online?
In order to purchase Apellis Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Dick’s Sporting Goods Buying Foot Locker Smart?
Last week, Dick’s Sporting Goods (NYSE:DKS) announced that it would…
Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
55
RGC alert for May 21
Regencell Bioscience Holdings [RGC] is down 3.24% over the past day.
Buy
64
AKRO alert for May 22
Akero Therapeutics [AKRO] is up 1.56% over the past day.
Buy
86
AGYS alert for May 22
Agilysys [AGYS] is down 1.32% over the past day.
